Blood test may let some stomach cancer patients skip harsh chemo
NCT ID NCT07565857
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a personalized blood test (Signatera) can identify gastric cancer patients who, after surgery, have no detectable cancer DNA and can safely receive a milder immunotherapy (durvalumab) instead of standard chemotherapy. About 1000 adults with stage II-IVa gastric cancer will be enrolled. The goal is to see if this approach maintains similar cancer-free survival while reducing treatment side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Signatera blood test (ctDNA monitoring) and durvalumab (immunotherapy)
What this could lead to
If successful, this could show that some patients with gastric cancer can safely skip intensive chemotherapy after surgery, reducing side effects while maintaining similar outcomes.
What could go wrong
This is an early-stage study (Phase NA) with 1000 participants, and the approach may not prove non-inferior to standard care. The blood test may miss some recurrences, and durvalumab has its own risks like immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••